Circle faces 'medium-term' risks from slow USDC growth, rising distribution costs: Mizuho https://t.co/cRF45E6UmM ...

Coinbase's Q2 earnings point to shrinking USDC margins for Circle, Mizuho says https://t.co/CKjcoMVuRy ...

Core Viewpoint - Advanced Micro Devices (AMD) has received a positive endorsement from BofA Securities, maintaining a 'Buy' rating and raising its price target from $175 to $200, indicating a potential increase of about 15% from its last closing price of $173 [1][4]. Group 1: Price Target and Stock Performance - The new price target of $200 represents a 15% increase from AMD's last closing price of $173 [1]. - AMD's stock has rallied 11% over the past week and ended the previous session up over 4% [1]. Group 2: Earnings Expectations and Revenue Projections - BofA expects AMD to exceed consensus in both Q2 and Q3 earnings, forecasting revenues of $7.5 billion and $8.5 billion, respectively [7]. - For the full year 2025, BofA projects AMD's revenue to reach $33 billion and earnings per share of $4.10, both surpassing current Wall Street estimates [7]. Group 3: Market Opportunities and Drivers - Potential resumption of AI chip shipments to China in the second half of the year could contribute up to $1 billion in sales in 2025 and as much as $2 billion by 2026 [4]. - AMD is benefiting from stronger-than-expected pricing for its MI355X chips, with units selling for over $20,000, exceeding the consensus estimate of $17,000 [5]. - Strong demand for cloud-related GPUs, improving year-over-year comparisons in the PC segment, and steady enterprise interest from companies like Hewlett Packard Enterprise and Texas Instruments are also positive drivers [5]. Group 4: Market Share Projections - AMD is projected to capture more than 30% of the global CPU market by 2026, up from just under 20% in 2023 [8]. - Its share of the competitive AI GPU space could grow to 4% to 5%, supported by strategic shifts and manufacturing uncertainties at Intel [8]. Group 5: Analyst Ratings - Wall Street remains bullish on AMD stock, with Goldman Sachs reiterating a 'Buy' rating with a $140 target, while HSBC upgraded AMD to 'Buy' with a $200 target [8][9]. - Citi maintained a 'Hold' but raised its target from $120 to $145, indicating improved expectations [9].

Mizuho Chief Executive Officer Masahiro Kihara signaled he is confident the Japanese lender can meet its long-term target of about ¥1 trillion ($6.8 billion) in annual profit https://t.co/BsMnhtk9qa ...

Market Trend & Industry Dynamics - JPMorgan is planning to charge fintech companies for accessing customer bank account information, leading to a sell-off in fintech stocks like PayPal (down 6%) and Block (down 5%) [1] - The move by JPMorgan is seen as defensive, indicating that fintech companies are successfully attracting customers from traditional banks and impacting areas like buy now pay later [2] - Fintech companies rely on customer data obtained through services like Plaid to properly underwrite accounts [4] Potential Risks & Opportunities - The cost imposed by JPMorgan could be an added expense for fintech companies [5] - The rapid growth in account numbers and buy now pay later services may offset any additional costs incurred [6] - Visa's previous attempt to acquire Plaid in 2019 suggests the significant value of the data Plaid provides [5] Company Strategy - JPMorgan's action is interpreted as a defensive strategy to monetize customer data access, potentially due to diversification of customer business with other players [6]

Mizuho raised ¥14.3 billion ($97 million) for its latest startup fund, as Japanese banks delve deeper into arranging credit for new ventures https://t.co/4R3LHD8Et3 ...

人事变动 - 三名高级管理人员已离开瑞穗在新加坡和伦敦的外汇和利率交易团队[1]

Obesity Drug Market & Competition - Amgen's once-monthly weight loss shot, Maritide, showed patients without type 2 diabetes losing an average of 20% of their body weight after one year, but with a high rate of side effects and discontinuations [1] - Eli Lilly appears to be leading the obesity drug race with a safe oral candidate and an injectable (amalin) that provides weight loss with less muscle mass loss [2] - Novo Nordisk is facing challenges with disappointing Kaggarma data, while Eli Lilly is presenting positive results [2] - Novo Nordisk currently holds 33% of the market share, but Eli Lilly's oral data looks promising [4] - The market may not be seeking a 25% weight loss if other options offer around 22% [5] Amgen's Valuation & Pharma Sector - Amgen's stock dropped almost 6% after disappointing results for its weight loss shot [1] - Amgen is trading at approximately 12-13 times next year's numbers, which may not be considered cheap given the current pharma multiples and revenue cliffs [7][8] - The average pharma multiple is around 10 [7] - Over 50% of revenue for companies like Merck and Bristol-Myers Squibb will disappear by the end of the decade [8] Biotech & M&A - Biotech has had a decent run, with potential catalysts for M&A activity [9] - Despite potential asset quality concerns, increased M&A activity is expected in the biotech sector due to revenue degradation at the pharma level [11] - Big Pharma companies need to pursue M&A, with Pfizer, having spent $60 billion since the pandemic, actively seeking more assets, potentially in the obesity area [12]

Investment Rating - The report rates Mizuho as Overweight (OW), Mitsubishi UFJ Financial Group (MUFG) as Neutral (N), and Sumitomo Mitsui Financial Group (SMFG) as Neutral (N) [2][3][6]. Core Insights - Mizuho is projected to be the only mega bank with a return on equity (ROE) exceeding 11% [3][6]. - The report indicates a downgrade for Chongqing Rural Commercial Bank (CRCB) to Neutral due to a decline in dividend attractiveness following a 46% year-to-date rally [11]. - A survey of over 500 investors at the Asia Credit Conference suggests a majority expect the US 10-year yield to exceed 4% by the end of 2025 [15]. Detailed Highlights - Mizuho is the only mega bank forecasted to achieve an ROE above 11%, with a CET1 target of 10% and plans for accelerated buybacks [3][6]. - The Japan Consumer Finance sector is experiencing rising revolving credit card interest rates, now reaching the regulatory ceiling of 18%, while demand remains resilient despite inflation [6][7]. - The dividend yield for CRCB is now 4.3%, which is less attractive compared to peers, following its inclusion in the CSI300 Index [11][12]. Sector Key Newsflow - The report highlights that major players in Japan's consumer finance are raising interest rates on revolving credit cards to the regulatory limit, with Credit Saison leading the way [7][8]. - The Bank of Japan (BoJ) is expected to continue its quantitative tightening (QT) at a pace of -Y400 billion per quarter beyond Q2 2026, with potential adjustments based on market conditions [6][7]. - The report notes that the overall dividend play in the banking sector is becoming less attractive, particularly for CRCB, as improvements are already priced in [11].

Group 1 - Citi has identified Advanced Micro Devices (AMD) as better positioned to challenge Nvidia following strategic developments, maintaining a 'Neutral' rating with a price target of $100, indicating a 12.9% downside from the current price of $114.74 [1] - AMD's restructured acquisition of ZT Systems is seen as a critical move to enhance long-term competitiveness against Nvidia, with the acquisition now valued at $3 billion after divesting manufacturing operations [2] - The cost to retain ZT's engineering team is estimated at $1.6 billion, allowing AMD to focus on R&D and engineering talent, which is crucial for competing in the AI and high-performance computing landscape [3] Group 2 - Wells Fargo has reiterated an 'Overweight' rating on AMD with a price target of $120, citing ongoing momentum in rack-scale AI infrastructure as a key driver [4] - Following the acquisition of ZT Systems' manufacturing operations, Wells Fargo emphasized that this move strengthens AMD's rack-scale strategy ahead of the MI400-series GPUs launch in the second half of 2026 [5] - Mizuho analyst raised AMD's price target to $135 with a 'Buy' rating, following a $10 billion multi-year AI infrastructure deal with Saudi-based startup Humain, which could significantly accelerate AMD's data center segment growth [7][8]